Lucid Diagnostics(LUCD) - 2025 Q3 - Quarterly Results

Financial Performance - Processed 2,841 EsoGuard tests and recognized 3Q25 revenue of $1.2 million, with operating expenses of approximately $13.0 million[7] - GAAP net loss attributable to common stockholders was approximately $10.4 million or $(0.10) per common share[9] - Non-GAAP adjusted loss for 3Q25 was approximately $10.3 million or $(0.10) per common share[9] - EsoGuard related revenues for the nine months ended September 30, 2025, were $3.2 million, compared to $3.1 million for the same period in 2024[9] - Operating expenses for the nine months ended September 30, 2025, were approximately $38.8 million, compared to $36.8 million for the same period in 2024[9] Cash Position - Ended 3Q25 with over $47 million in proforma cash, extending runway through 2026[7] - Completed a public offering netting approximately $27.0 million in proceeds during the quarter[7] Market Access and Coverage - Unanimous expert consensus from the Multi-Jurisdictional Contractor Advisory Committee supports Medicare coverage for EsoGuard[5] - The company is preparing to accelerate EsoGuard commercialization as Medicare coverage and other reimbursement milestones are secured[5] Leadership Changes - Appointed Danielle Scelfo as Senior Vice President, Market Access & Government Affairs to enhance market access infrastructure[7]